Trial Profile
A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Riluzole (Primary) ; Sorafenib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 22 Sep 2023 Planned End Date changed from 9 Sep 2023 to 9 Sep 2024.
- 10 Sep 2022 Planned End Date changed from 1 Aug 2022 to 9 Sep 2023.
- 18 May 2022 Planned End Date changed from 1 May 2022 to 1 Aug 2022.